Evaluation of therapeutic answer: Role of isotopic imaging;Évaluation de la réponse thérapeutique en cancérologie: Place de l'imagerie isotopique

Bulletin du Cancer

Volumn 93, Issue 12, 2006, Pages 1191-1199

  Cachin, Florent ^a,b   Kelly, Antony ^a   Maublant, Jean ^a,b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

Author keywords

18FDG; Molecular imaging; PET CT; Scintigraphy; Therapeutic response

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID TC 99M; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; GLUCOSE DERIVATIVE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201; DIAGNOSTIC AGENT; GALLIUM; RADIOPHARMACEUTICAL AGENT; TECHNETIUM DERIVATIVE; TECHNETIUM TC 99M DIPHOSPHONATE; THALLIUM;

ACCURACY; ARTICLE; BONE METASTASIS; BRAIN TUMOR; BREAST TUMOR; CANCER; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIGESTIVE SYSTEM CANCER; GENE THERAPY; HEAD AND NECK CANCER; HEALTH CARE FACILITY; HODGKIN DISEASE; HUMAN; LUNG CANCER; MEDICAL ASSESSMENT; METHODOLOGY; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; SARCOMA; TREATMENT RESPONSE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; MONITORING; NEOPLASM; RADIOGRAPHY; REVIEW; SCINTISCANNING; TREATMENT OUTCOME;

DIPHOSPHONATES; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HUMANS; MONITORING, PHYSIOLOGIC; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TECHNETIUM COMPOUNDS; TECHNETIUM TC 99M SESTAMIBI; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 33846053550     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2006.0145     Document Type: Article

References (49)

1. Kostakoglu L, Yeh SD, Portlock C, Heelan R, Yao TJ, Niedzwiecki D, et al. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992; 33: 345-50.
2. Vose JM, Bierman PJ, Anderson JR, Harrison KA, Dalrymple GV, Byar K, et al. Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 2473-9.
3. Front D, Ben-Haim S, Israel O, Epelbaum R, Haim N, Even-Sapir E, et al. Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology 1992; 182: 359-63.
4. Front D, Bar-Shalom R, Mor M, Haim N, Epelbaum R, Frenkel A, et al. Aggressive non-Hodgkin lymphoma: early prediction of outcome with 67Ga scintigraphy. Radiology 2000; 214: 253-7.
5. Omar WS, Eissa S, Moustafa H, Farag H, Ezzat I, Abdel-Dayem HM. Role of thallium-201 chloride and Tc-99m methoxy-isobutyl-isonitrite (sestaMIBI) in evaluation of breast masses: correlation with the immunohistochemical characteristic parameters (Ki-67, PCNA, Bcl, and angiogenesis) in malignant lesions. Anticancer Res 1997; 17: 1639-44.
6. Caluser CI, Abdel-Dayem HM, Macapinlac HA, Scott A, Healey JH, Huvos A, et al. The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas. Eur J Nucl Med 1994; 21: 1198-205.
7. Abe H, Tervi S, Terauchi T, Muramatsu Y, Yokayama R, Ohtomo K, et al. Comparison of Tc-99m pertechnetate with Tl-201 and Ga-67 scintigaphy of malignant soft-tissue tumors. Clin Nucl Med 1997; 22: 38-41.
8. Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healey JH, Meyers P, et al. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. Cancer 1997; 80: 1507-12.
9. Choong PF, Nizam I, Ngan SY, Schlict S, Powell G, Slavin J, et al. Thallium-201 scintigraphy: a predictor of tumour necrosis in soft tissue sarcoma following preoperative radiotherapy? Eur J Surg Oncol 2003; 29: 908-15.
10. Kallen K, Geijer B, Malmstrom P, Andersson AM, Holtas S, Ryding E, et al. Quantitative 201Tl SPET imaging in the follow-up of treatment for brain tumour: a sensitive tool for the early identification of response to chemotherapy? Nucl Med Commun 2000; 21: 259-67.
11. Vallejos V, Balana C, Fraile M, Roussos Y, Capellades J, Cuadras P, et al. Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas. J Neurooncol 2002; 59: 81-90.
12. Tomura N, Izumi J, Anbai A, Takahashi S, Sakuma I, Omachi K, et al. Thallium-201 SPECT in the evaluation of early effects on brain tumors treated with stereotactic irradiation. Clin Nucl Med 2005; 30: 83-6.
13. Kimura T, Sako K, Tanaka K, Gotoh T, Yoshida H, Aburano T, et al. Evaluation of the response of metastatic brain tumors to stereotactic radiosurgery by proton magnetic resonance spectroscopy, 201TlCl single-photon emission computerized tomography, and gadolinium-enhanced magnetic resonance imaging. J Neurosurg 2004; 100: 835-41.
14. Maublant J, Baggott J. Technetium-99m-sestamibi cellular uptake: passive or secondary active transport? J Nucl Med 1997; 38: 1170.
15. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis (2-methoxyisobutylisonitrile)- technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990; 50: 2198-202.
16. Piwnica-Worms D, Rao VV, Kronauge JF, Croop JM. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation. Biochemistry 1995; 34: 12210-20.
17. Kostakoglu L, Ruacan S, Ergun EL, Sayek I, Elahi N, Bekdik CF. Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer. J Nucl Med 1998; 39: 1021-6.
18. Del Vecchio S, Ciarmiello A, Pace L, Potena MI, Carriero MV, Mainolfi C, et al. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients. J Nucl Med 1997; 38: 1348-51.
19. Cayre A, Cachin F, Maublant J, Mestas D, Feillel V, Fernere JP, et al. Single static view 99mTc-sestamibi scintimammography predicts response to neoadjuvant chemotherapy and is related to MDR expression. Int J Oncol 2002; 20: 1049-55.
20. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography. Cancer 1999; 85: 2410-23.
21. Cwikla JB, Buscombe JR, Barlow RV, Kelleher SM, Parbhoo SP, Crow J, et al. The effect of chemotherapy on the uptake of technetium-99m sestamibi in breast cancer. Eur J Nucl Med 1997; 24: 1175-8.
22. Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Lawton TJ, et al. Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer 2005; 103: 680-8.
23. Vogel CL, Schoenfelder J, Shemano I, Hayes DF, Gams RA. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol 1995; 13: 1123-8.
24. Van Schelven WD, Pauwels EK. The flare phenomenon: far from fair and square. Eur J Nucl Med 1994; 21: 377-80.
25. DeMeo JH, Balseiro J, Cole TJ. Etidronate sodium therapy. A cause of poor skeletal radiopharmaceutical uptake. Semin Nucl Med 1991; 21: 332-4.
26. Salgia R, Demetri GD, Kaplan WD. Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report. Cancer 1994; 74: 1887-90.
27. Rossleigh MA, Lovegrove FT, Reynolds PM, Byrne MJ, Whitney BP. The assessment of response to therapy of bone metastases in breast cancer. Aust N Z J Med 1984; 14: 19-22.
28. Saip P, Tenekeci N, Aydiner A, Dincer M, Inanc S, Demir C, et al. Response evaluation of bone metastases in breast cancer: value of magnetic resonance imaging. Cancer Invest 1999; 17: 575-80.
29. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-82.
30. Karidioula I, De Freitas D, Cachin F, Geissler B, Jullien P, Maublant J. Utilization of CT images for the quantification of FDG uptake. Nucl Imag Meth 2005; (in press).
31. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998; 39: 1030-3.
32. Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 2004; 31: 1471-8.
33. Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer 2001; 91: 302-10.
34. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity. Br J Haematol 2001; 115: 272-8.
35. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-81.
36. Hutchings M, Loft A, Hansen MT, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-9.
37. Mac Manus MP, Hicks RJ, Matthews JP, McKenzie A, Rischin D, Salminen EK, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21: 1285-92.
38. Ryu JS, Choi NC, Fischman AJ, Lynch TJ, Mathisen DJ. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer 2002; 35: 179-87.
39. Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22: 900-8.
40. Brun E, Kjellen E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002; 24: 127-35.
41. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 2005; 46: 983-95.
42. Spaepen K, Stroobants S, Dupont P, Thomas J, Vandenberghe P, Balzarini J, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol 2001; 115: 272-8.
43. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004; 101: 1776-85.
44. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004; 22: 2167-71.
45. Manus MP, Hicks RJ, Matthews JP, Wirth A, Rischin D, Ball DL. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 2005; 49: 95-108.
46. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001; 19: 2797-803.
47. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-65.
48. Hicks RJ, Mac Manus MP, Matthews JP, Hogg A, Binns D, Rischin D, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004; 60: 412-8.
49. Hassaballa HA, Cohen ES, Khan AJ, Ali A, Bonomi P, Rubin DB. Positron emission tomography demonstrates radiation-induced changes to non-irradiated lungs in lung cancer patients treated with radiation and chemotherapy. Chest 2005; 128: 1448-52.